Literature DB >> 34989985

Results of Intrahepatic Cholangiocarcinoma Resections: a Single-Center Analysis.

Kutay Saglam1, Yusuf Murat Bag2, Zafer Bilen3, Burak Isik3, Cemalettin Aydin4, Sezai Yilmaz4.   

Abstract

INTRODUCTION: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary neoplasm of the liver after hepatocellular carcinoma (HCC). Although an underlying cause is not usually found, liver flukes, cirrhosis, primary sclerosing cholangitis, and viral hepatitis have been found to increase the risk in recent years. In this study, we aimed to present our experience on ICC and compare the outcomes of patients with a concomitant liver pathology and with incidentally detected ICC. PATIENTS AND METHODS: Thirty-three patients who underwent surgical resection for ICC were included in the study. Patients were divided into two groups, group one (with concomitant liver disease, n = 13) and group two (incidentally detected ICC, n = 18). Demographics, perioperative findings, pathological properties, recurrence rates, and survival rates were retrospectively analyzed and compared between the groups.
RESULTS: The mean age of patients was 59.77 ± 9.81 years, of whom sixteen (51.6%) were males. Thirteen patients (41.9%) had concomitant liver disease, the most common being chronic hepatitis B infection. Eighteen patients (58.1%) had incidentally detected ICC. There were no significant differences between the groups except for follow-up time and recurrence rate. The recurrence rate was significantly higher in the incidentally detected ICC group (61.1% versus 7.7%, p = 0.003). Follow-up time was significantly higher in patients with concomitant liver disease (42 versus 17.5 months, p = 0.007). The mortality rate was higher in the incidentally detected ICC group (55.6 to 23.1%, p = 0.071) but the difference did not reach statistical significance.
CONCLUSION: Surgical resection in ICC patients with underlying liver disease is associated with better prognosis than in incidentally detected ICC patients. Incidental ICC may be a different tumor with different biology, hence the high recurrence rates.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cholangiocytes; Hepatic malignancies; Liver; Tumor

Year:  2022        PMID: 34989985     DOI: 10.1007/s12029-021-00781-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  9 in total

1.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Oliver Clements; Joseph Eliahoo; Jin Un Kim; Simon D Taylor-Robinson; Shahid A Khan
Journal:  J Hepatol       Date:  2019-09-16       Impact factor: 25.083

3.  Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: Evidence from a systematic review and meta-analysis.

Authors:  Jie-Hui Tan; Wan-Yan Zhou; Lei Zhou; Rong-Chang Cao; Guo-Wei Zhang
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

4.  Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study.

Authors:  Xu-Feng Zhang; Jeffery Chakedis; Fabio Bagante; Eliza W Beal; Yi Lv; Matthew Weiss; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Oliver Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

5.  Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma.

Authors:  Diamantis I Tsilimigras; Kota Sahara; Anghela Z Paredes; Amika Moro; Rittal Mehta; Dimitrios Moris; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Feng Shen; Olivier Soubrane; Bas Groot Koerkamp; Itaru Endo; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2020-07-14       Impact factor: 3.452

6.  Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches.

Authors:  Diamantis I Tsilimigras; Kota Sahara; Lu Wu; Dimitrios Moris; Fabio Bagante; Alfredo Guglielmi; Luca Aldrighetti; Matthew Weiss; Todd W Bauer; Sorin Alexandrescu; George A Poultsides; Shishir K Maithel; Hugo P Marques; Guillaume Martel; Carlo Pulitano; Feng Shen; Olivier Soubrane; B Groot Koerkamp; Amika Moro; Kazunari Sasaki; Federico Aucejo; Xu-Feng Zhang; Ryusei Matsuyama; Itaru Endo; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2020-09-01       Impact factor: 14.766

7.  Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma.

Authors:  Jung Woong Seo; Byung Soo Kwan; Young Koog Cheon; Tae Yoon Lee; Chan Sup Shim; So Young Kwon; Won Hyeok Choe; Byung Chul Yoo; Jeong Min Yoon; Jung Hoon Lee
Journal:  Korean J Intern Med       Date:  2020-01-10       Impact factor: 2.884

8.  Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence.

Authors:  Kun-Ming Chan; Chun-Yi Tsai; Chun-Nan Yeh; Ta-Sen Yeh; Wei-Chen Lee; Yi-Yin Jan; Miin-Fu Chen
Journal:  BMC Gastroenterol       Date:  2018-12-04       Impact factor: 3.067

9.  Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments.

Authors:  Ilenia Bartolini; Matteo Risaliti; Laura Fortuna; Carlotta Agostini; Maria Novella Ringressi; Antonio Taddei; Paolo Muiesan
Journal:  Radiol Oncol       Date:  2020-07-29       Impact factor: 2.991

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.